Chemotherapy has long been a cornerstone of treatment, particularly for aggressive and advanced breast cancers, and it remains the backbone of HER2-targeted therapies [3,4], and endocrine treatments [5] are often added. The gene discussed is ERBB2; the disease is breast carcinoma.